
Fziomed has initiated commercialization of Oxiplex gel in the United States, indicated for reducing postoperative leg pain and neurological symptoms in adult patients undergoing lumbar spine procedures. According to the company, Oxiplex is the first and only FDA authorized intraoperative gel specifically designed for this indication.
Fziomed’s Oxiplex is an absorbable, clear gel applied directly to nerves and surrounding tissues during surgery immediately prior to closure. In spine surgery, Oxiplex acts as a temporary physical barrier between adjacent tissues and has been shown in multiple peer-reviewed publications to reduce postoperative leg pain and neurological symptoms. Oxiplex gel has been available outside the United States since 2002 and has been used in more than 750,000 spine procedures worldwide for postoperative adhesion prevention.
Source: Fziomed, Inc.
Fziomed has initiated commercialization of Oxiplex gel in the United States, indicated for reducing postoperative leg pain and neurological symptoms in adult patients undergoing lumbar spine procedures. According to the company, Oxiplex is the first and only FDA authorized intraoperative gel specifically designed for this indication.
Fziomed's...
Fziomed has initiated commercialization of Oxiplex gel in the United States, indicated for reducing postoperative leg pain and neurological symptoms in adult patients undergoing lumbar spine procedures. According to the company, Oxiplex is the first and only FDA authorized intraoperative gel specifically designed for this indication.
Fziomed’s Oxiplex is an absorbable, clear gel applied directly to nerves and surrounding tissues during surgery immediately prior to closure. In spine surgery, Oxiplex acts as a temporary physical barrier between adjacent tissues and has been shown in multiple peer-reviewed publications to reduce postoperative leg pain and neurological symptoms. Oxiplex gel has been available outside the United States since 2002 and has been used in more than 750,000 spine procedures worldwide for postoperative adhesion prevention.
Source: Fziomed, Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
PM
Patrick McGuire is an ORTHOWORLD Contributor.




